Celltrion’s Susbisidary Acquires Primary Care Product Assets for APAC Markets from Takeda (2020.06)

Celltrion has signed an agreement to acquire business rights several brands of Takeda Pharmaceutical for 332.4 billion won ($278.2 USD). The Deal allows Celltrion to secure patents, trademarks and sales rights for 18 prescription and over-the-counter brands in 9 markets including Thailand, Phillipines, Singapore, Malaysia, and Hong Kong. The deal marks Celltrion’s first large-scale M&A deal, giving Celltrion a gateway to strengthen its global R&D capabilities and sales channels.